July 29, 2024

Concerns About Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy—Reply

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In Reply We appreciate the comments from Cheng and Hsu regarding our study1 on the clinical effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA). Their observations bring valuable perspectives that merit further discussion.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Schwartz et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5ea38b6db64358757ef05 https://doi.org/https://doi.org/10.1001/jamapediatrics.2024.2594

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Newborn Screening for Spinal Muscular Atrophy in New York State2022 · 51 citations
2Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening2022 · 41 citations
3Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam—Part 2: Experience from a nusinersen clinical study2017 · 85 citations
4Assessment of Gross Motor Development in the who Multicentre Growth Reference Study2004 · 176 citations
5Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy2018 · 84 citations

Preguntar a la IA

Me gusta

Guardar